Rita Coelho

Dr. Rita Coelho


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2025 in DNA
Verified
Journal Article
Open access
PDF file
RRRicardo Roque
Ricardo Roque
RSRita Santos
Rita Santos
LSLuís Guilherme Henriques Barroso Santos
Luís Guilherme Henriques Barroso Santos
RCRita Coelho
Rita Coelho
IFIsabel Fernandes
Isabel Fernandes
Nuno Antunes BonitoNuno Antunes Bonito
Nuno Antunes Bonito
Background: Colorectal cancer (CRC) is the third most diagnosed cancer globally and the second leading cause of cancer-related deaths. Despite advancements, metastatic CRC (mCRC) has a five-year survival rate below 20%. Next-generation sequencing (NGS) is recommended nowadays to guide mCRC treatment; however, its clinical utility when compared with traditional molecular testing in mCRC is debated due to limited survival improvement and cost-effectiveness concerns. Methods: This retrospective study included mCRC patients (≥18 years) treated at a single oncology centre who underwent NGS during treatment planning. Tumour samples were analysed using either a 52-gene Oncomine™ Focus Assay or a 500+-gene Oncomine™ Comprehensive Assay Plus. Variants were classified by clinical significance (ESMO ESCAT) and potential benefit (ESMO-MCBS and OncoKBTM). The Mann–Whitney and Chi square tests were used to compare characteristics of different groups, with significance at p < 0.05. Results: Eighty-six metastatic colorectal cancer (mCRC) patients were analysed, all being MMR proficient. Most cases (73.3%) underwent sequencing at diagnosis of metastatic disease, using primary tumour samples (74.4%) and a focused NGS assay (75.6%). A total of 206 somatic variants were detected in 86.0% of patients, 31.1% of which were classified as clinically significant, predominantly KRAS mutations (76.6%), with G12D and G12V variants as the most frequent. Among 33.7% RAS/BRAF wild-type patients, 65.5% received anti-EGFR therapies. Eleven patients (12.8%) had other actionable variants which were ESCAT level I-II, including four identified as TMB-high, four KRAS G12C, two BRAF V600E, and one HER2 amplification. Four received therapies classified as OncoKbTM level 1–2 and ESMO-MCBS score 4, leading to disease control in three cases. Conclusions: NGS enables the detection of rare variants, supports personalised treatments, and expands therapeutic options. As new drugs emerge and genomic data integration improves, NGS is poised to enhance real-world mCRC management.

1 January 2026 in European Journal of Gynaecological Oncology
Verified
Journal Article
Open access
PDF file
IFIara Fernandes
Iara Fernandes
RCRita Coelho
Rita Coelho
MFMargarida Figueiredo-Dias
Margarida Figueiredo-Dias
RRRicardo Roque
Ricardo Roque
Correction: The role of progesterone in ovarian cancer from pathogenesis to personalized therapy: an updated mini-review. Iara Fernandes,Rita Coelho,Margarida Figueiredo-Dias,Ricardo Roque. European…

27 December 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
RRRicardo Roque
Ricardo Roque
RSRita Santos
Rita Santos
LSLuís Guilherme Henriques Barroso Santos
Luís Guilherme Henriques Barroso Santos
RCRita Coelho
Rita Coelho
IFIsabel Fernandes
Isabel Fernandes
Nuno Antunes BonitoNuno Antunes Bonito
Nuno Antunes Bonito
Background : Colorectal cancer (CRC) is the third most diagnosed cancer globally and the second leading cause of cancer-related deaths. Despite advancements, metastatic CRC (mCRC) has a five-year survival rate below 20%. Next-generation sequencing (NGS) is recommended nowadays to guide mCRC treatment, however its clinical utility when compared with traditional molecular testing in mCRC is debated due to limited survival improvement and cost-effectiveness concerns. Methods : This retrospective study included mCRC patients (≥18 years) treated at a single oncology center who underwent NGS during treatment planning. Tumour samples were analyzed using either a 52-gene Oncomine™ Focus Assay or a 500+ gene Oncomine™ Comprehensive Assay Plus. Variants were classified by clinical significance (ESMO ESCAT) and potential benefit (ESMO-MCBS and OncoKBTM). The Mann-Whitney and Chi square tests were used to compare characteristics of different groups, with significance at p<0.05. Results : Eighty-six metastatic colorectal cancer (mCRC) patients were analysed, all MMR proficient. Most cases (73.3%) underwent sequencing at diagnosis of metastatic disease, using primary tumour samples (74.4%) and a focused NGS assay (75.6%). A total of 206 somatic variants were detected in 86.0% of patients, 31.1% of which were classified as clinically significant, predominantly KRAS mutations (76.6%), with G12D and G12V variants as the most frequent. Among 33.7% RAS/BRAF wild-type patients, 65.5% received anti-EGFR therapies. Eleven patients (12.8%) had other actionable variants ESCAT level I-II, including four identified as TMB-high, four KRAS G12C, two BRAF V600E and one HER2 amplification. Four received therapies classified as OncoKbTM level 1-2 and ESMO-MCBS score 4, leading to disease control in three cases. Conclusions : NGS enables the detection of rare variants, supports personalized treatments, and expands therapeutic options. As new drugs emerge and genomic data integration improves, NGS is poised to enhance real-world mCRC management.